Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA sets date to discuss Macugen NDA

June 1, 2004

Dosing commences in phase II trial of Albuferon for chronic HCV

June 1, 2004

Pharmaceutical Resources changes name to Par Pharmaceutical Companies

June 1, 2004

Approval for Gonal-f Pen for infertility

June 1, 2004

LC16m8 smallpox vaccine demonstrates effectiveness in animal studies

June 1, 2004

European approval for new Enbrel indication

June 1, 2004

SciClone and Nektar Therapeutics collaborate on pegylated Zadaxin

June 1, 2004

Novel small molecule inhibitor of human rotavirus

June 1, 2004

Novel anti-HIV agent targets RNase H activity

June 1, 2004

Oncolytic adenovirus targets colon cancer cells with deregulated wnt pathway in vivo

June 1, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal
BioWorld
Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui...
Unique trial strategy muddies the ODAC waters for camizestrant
BioWorld
Following a discussion that focused more on a new personalized trial strategy rather than the proposed therapy, the U.S. FDA’s Oncologic Drugs Advisory Committee...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...